NCT07820150Not yet recruiting
Hyperparathyroidism and Dialysis Adequacy in Hemodialysis Patients
Prevalence of Hyperparathyroidism Among End-Stage Renal Disease Patients on Regular Hemodialysis and Its Relation to Dialysis Adequacy
Source: ClinicalTrials.gov · Last updated 15 Sept 2026
Brief summary (registry, in English)
This cross-sectional study aims to determine the prevalence of secondary hyperparathyroidism among end-stage renal disease patients on regular hemodialysis and to evaluate its relationship with dialysis adequacy at Assiut University Hospitals.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 130 (estimated)
- First submitted
- 9 Sept 2026
- Start date
- 10 Sept 2026
- Primary completion date
- 10 Sept 2027
- Lead sponsor
- Assiut University
- Diseases
- Chronic kidney disease
- NCT number
- NCT07820150
What you commit to
- Study type: Observational
- Planned participants: 130
- From 10 Sept 2026 to the primary completion date, 10 Sept 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- \- Primary hyperparathyroidism or prior parathyroidectomy
Other illness
- Active severe infections or acute systemic illnesses
- Active malignancy
Other
- Severe hepatic dysfunction or chronic liver cirrhosis
Who the study is looking for
- \- Age 18 years or older
- Diagnosed with end-stage renal disease
- Maintained on regular thrice-weekly hemodialysis for at least three consecutive months
- Written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.